Background:Ly6G (Lymphocyte antigen 6 complex locus G6D) is a component of the myeloid differentiation antigen Gr-1, together with Ly6C. The Ly6G is expressed by myeloid derived cells and can be used as a marker for detection of neutrophils and granulocytic MDSCs. Ly6G has also been implicated in the development of antitumor responses.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis of stained tissue microarray using the appropriate positive and negative tissue field of views. 

Recommended Usage:Mouse FFPE: 3 ug/mL dilution.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References
Vincenzo Bronte et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7: 12150.
Gaël Boivin et al. Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy. Oncoimmunology. 2021; 10(1): 1876597.

* Conjugate tested on mouse tissue.